Cutia Therapeutics (HKG:2487)
Hong Kong · Delayed Price · Currency is HKD 4.750
-0.090 (-1.86%)
Apr 17, 2026, 3:41 PM HKT
Cutia Therapeutics Revenue
In the year 2025, Cutia Therapeutics had annual revenue of 336.15M CNY with 20.22% growth. Cutia Therapeutics had revenue of 269.86M in the half year ending December 31, 2025, with 161.29% growth.
Revenue
336.15M CNY
Revenue Growth
+20.22%
P/S Ratio
4.70
Revenue / Employee
1.11M CNY
Employees
304
Market Cap
1.76B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 336.15M | 56.54M | 20.22% |
| Dec 31, 2024 | 279.62M | 141.99M | 103.17% |
| Dec 31, 2023 | 137.62M | 126.26M | 1,110.83% |
| Dec 31, 2022 | 11.37M | 9.33M | 457.70% |
| Dec 31, 2021 | 2.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 2.00B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.45B |
| Mabpharm | 718.98M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| CANbridge Pharmaceuticals | 55.62M |
| Kintor Pharmaceutical | 36.37M |
| Zhaoke Ophthalmology | 35.58M |
| Transcenta Holding | 8.27M |